Pre-clinical testing of therapeutic to improve egg quality and IVF out
Research type
Research Study
Full title
Research aiming to improve egg quality and IVF outcomes using pre- clinical testing of a novel therapeutic
IRAS ID
356803
Contact name
Alexandre Webster
Contact email
Sponsor organisation
U-Ploid Biotechnologies
Duration of Study in the UK
0 years, 6 months, 3 days
Research summary
A healthy egg and sperm will both contribute exactly one copy of each of their chromosomes to an embryo. During reproductive ageing, eggs often contribute the wrong number of chromosomes to an embryo. This significantly reduces the success of fertility treatments, accounting for 80% of IVF failures and more than 50% of miscarriages. As more people plan to start their families later in life, effective solutions are required to improve fertility outcomes and remove barriers to accessing effective care.
U-Ploid Biotechnologies has developed a novel therapeutic that has been shown in animal studies to maintain the correct number of chromosomes in aged eggs and promote healthy embryo development.
Care Fertility is collaborating with U-Ploid Biotechnologies to conduct pre-clinical studies on donor eggs to assess the efficacy and safety of the therapeutic. Donor eggs will be randomised into a treatment and non-treatment arm, and studied under the microscope to evaluate whether the eggs chromosomes. No eggs will be fertilised in this study. No embryos will be created in this study.
Successful pre-clinical studies will enable U-Ploid Biotechnologies to apply for a clinical trial to evaluate whether the therapeutic can improve fertility outcomes for female patients in their mid-30's to 40’s.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
25/WM/0092
Date of REC Opinion
24 Jun 2025
REC opinion
Further Information Favourable Opinion